ストックスクリーナーアプリを入手
4.26
3.40%
-0.15
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com
Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance
(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World
Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail
How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com
Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus
Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus
Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating - marketscreener.com
Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline - TipRanks
Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Transcript : Y-mAbs Therapeutics, Inc.Special Call - marketscreener.com
Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating - marketscreener.com
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress - TipRanks
Y-mAbs Therapeutics Announces Positive Phase 1 Trial Results for GD2-SADA in Metastatic Solid Tumors and Expands Radiopharmaceutical Pipeline - Nasdaq
Clinical Trial Success: Y-mAbs Breakthrough in Cancer Treatment Shows Promise with Novel Radiopharmaceutical - Stock Titan
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 - MSN
Y-mAbs Therapeutics, Inc. Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - marketscreener.com
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - The Manila Times
Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting - Nasdaq
Y-mAbs Advanced Cancer Trial Breakthrough: Key Data Coming for Revolutionary GD2-SADA Treatment - Stock Titan
Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles - Investing.com Canada
Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles By Investing.com - Investing.com South Africa
What is HC Wainwright’s Forecast for YMAB FY2026 Earnings? - Defense World
HC Wainwright Issues Pessimistic Estimate for YMAB Earnings - Defense World
Caligan Partners LP Increases Stake in Y-mAbs Therapeutics Inc - GuruFocus
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright - Defense World
What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics - Benzinga
H.C. Wainwright Adjusts Price Target for Y-mAbs Therapeutics (YM - GuruFocus
Price T Rowe Associates Inc. MD Cuts Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
FY2025 EPS Estimates for YMAB Increased by Analyst - Defense World
Formulation Is Key For Y-mAbs' Self-Assembling Antibody - Bioprocess Online
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Oppenheimer Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Q2 EPS Estimates for Y-mAbs Therapeutics Cut by Wedbush - Defense World
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates - MSN
Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook - TipRanks
Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Y-mAbs Therapeutics (YMAB) Maintains "Outperform" Rating, PT Low - GuruFocus
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Y-mAbs Therapeutics outlines Q2 revenue guidance of $17M–$19M amid DANYELZA NCCN guideline inclusion and expanded ex-U.S. growth - MSN
Y-mAbs Therapeutics (YMAB) Maintains - GuruFocus
1.45%
0.86%
大文字化:
|
ボリューム (24 時間):